Capabilities
Discovery Chemistry
Discovery Chemistry That Advances Programs, Not Just Molecules
At Wilmington PharmaTech, discovery chemistry is built around translational problem-solving. Our teams focus on advancing complex small-molecule candidates, with a clear understanding of how early chemistry decisions affect downstream development, manufacturability, and regulatory success.
Clients engage Wilmington PharmaTech when discovery programs involve challenging chemistry, compressed timelines, or a need to move efficiently from early material generation into development. Our approach emphasizes scientific rigor, speed, and continuity, ensuring promising candidates are positioned for successful progression rather than stalled by avoidable technical risk.
Target Synthesis and Early Lead Generation
Wilmington PharmaTech discovery chemistry teams support early programs through custom target synthesis and scaffold development tailored to client objectives. Our chemists routinely work with novel and challenging chemical structures, generating high-quality material to enable biological evaluation and informed decision-making.
Experience across a wide range of synthetic transformations allows Wilmington PharmaTech to:
-
Rapidly assess feasibility
-
Explore alternative routes
-
Adapt chemistry strategies as targets evolve
This flexibility is particularly valuable for programs where initial literature routes are impractical or poorly suited for scale.
Hear our Founder and our Managing Director describe how Wilmington PharmaTech improves the R&D process and tackles the toughest chemistry challenges for its clients.
Lead Selection and Optimization with Development in Mind
Lead optimization at Wilmington PharmaTech goes beyond iterative analog synthesis. Our scientists evaluate synthetic efficiency, structural complexity, and potential scale-up challenges alongside biological performance.
By considering factors such as step count, yield, impurity formation, and functional group liability early, Wilmington PharmaTech helps clients identify lead candidates that balance potency with practical developability. This perspective reduces rework later in development and supports smoother transitions into process optimization.
Chiral and Achiral Purification Expertise
Purification strategy is a critical component of successful discovery chemistry. Wilmington PharmaTech provides both chiral and achiral purification support to meet early material needs while informing scalable solutions.
Chiral Seperation and Purification
Phase 1 is used to find out several promising methods of separation.
Phase 2 is used to develop an optimized, robust method which is scalable for large scale production with a tentative (non-binding) productivity in KKD ((kg of racemate material/kg of chiral stationary phase/day).
For chiral purification besides purifying target molecule enantiomer; the chemical purity (achiral) is also checked.
Our scientists develop purification approaches that consider yield, throughput, and impurity control, ensuring discovery-scale methods can be translated effectively as programs progress. This expertise supports efficient material generation without introducing barriers to later development.
DMPK, Toxicology, and Integrated Discovery Support
Wilmington PharmaTech supports discovery programs beyond synthesis through close collaboration with trusted partners providing DMPK, toxicology, and related studies. Our chemists routinely generate metabolites, reference standards, and specialized compounds to support pharmacokinetic evaluation and early safety assessment. Services offered include:
Services offered include:
-
Discovery Biology
-
Medicinal Chemistry
-
Custom Synthesis
-
Screening PK
-
ADME
-
Pharmacology Testing
This integrated support enables clients to move efficiently through early decision points while maintaining continuity between chemistry, biology, and emerging development requirements.
Additional
Capabilities
SEND AN INQUIRY
We’re Ready to Start
Looking to connect? We welcome the opportunity to discuss your needs and questions.